PMID- 36986633
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231106
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 15
IP  - 3
DP  - 2023 Feb 26
TI  - Recent Progress of Lipid Nanoparticles-Based Lipophilic Drug Delivery: Focus on 
      Surface Modifications.
LID - 10.3390/pharmaceutics15030772 [doi]
LID - 772
AB  - Numerous drugs have emerged to treat various diseases, such as COVID-19, cancer, 
      and protect human health. Approximately 40% of them are lipophilic and are used 
      for treating diseases through various delivery routes, including skin absorption, 
      oral administration, and injection. However, as lipophilic drugs have a low 
      solubility in the human body, drug delivery systems (DDSs) are being actively 
      developed to increase drug bioavailability. Liposomes, micro-sponges, and 
      polymer-based nanoparticles have been proposed as DDS carriers for lipophilic 
      drugs. However, their instability, cytotoxicity, and lack of targeting ability 
      limit their commercialization. Lipid nanoparticles (LNPs) have fewer side 
      effects, excellent biocompatibility, and high physical stability. LNPs are 
      considered efficient vehicles of lipophilic drugs owing to their lipid-based 
      internal structure. In addition, recent LNP studies suggest that the 
      bioavailability of LNP can be increased through surface modifications, such as 
      PEGylation, chitosan, and surfactant protein coating. Thus, their combinations 
      have an abundant utilization potential in the fields of DDSs for carrying 
      lipophilic drugs. In this review, the functions and efficiencies of various types 
      of LNPs and surface modifications developed to optimize lipophilic drug delivery 
      are discussed.
FAU - Seo, Yoseph
AU  - Seo Y
AD  - Department of Chemical Engineering, Kwangwoon University, 20 Kwangwoon-Ro, 
      Nowon-Gu, Seoul 01897, Republic of Korea.
FAU - Lim, Hayeon
AU  - Lim H
AD  - Department of Chemical Engineering, Kwangwoon University, 20 Kwangwoon-Ro, 
      Nowon-Gu, Seoul 01897, Republic of Korea.
FAU - Park, Hyunjun
AU  - Park H
AUID- ORCID: 0000-0002-8176-0460
AD  - Department of Chemical Engineering, Kwangwoon University, 20 Kwangwoon-Ro, 
      Nowon-Gu, Seoul 01897, Republic of Korea.
FAU - Yu, Jiyun
AU  - Yu J
AD  - Department of Chemical Engineering, Kwangwoon University, 20 Kwangwoon-Ro, 
      Nowon-Gu, Seoul 01897, Republic of Korea.
FAU - An, Jeongyun
AU  - An J
AD  - Department of Chemical Engineering, Kwangwoon University, 20 Kwangwoon-Ro, 
      Nowon-Gu, Seoul 01897, Republic of Korea.
FAU - Yoo, Hah Young
AU  - Yoo HY
AUID- ORCID: 0000-0001-6701-6654
AD  - Department of Biotechnology, Sangmyung University, 20, Hongjimun 2-Gil, 
      Jongno-Gu, Seoul 03016, Republic of Korea.
FAU - Lee, Taek
AU  - Lee T
AD  - Department of Chemical Engineering, Kwangwoon University, 20 Kwangwoon-Ro, 
      Nowon-Gu, Seoul 01897, Republic of Korea.
LA  - eng
GR  - 2020003030001/Korea Ministry of Environment (MOE)/
PT  - Journal Article
PT  - Review
DEP - 20230226
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC10058399
OTO - NOTNLM
OT  - PEGylation
OT  - chitosan coating
OT  - drug delivery systems
OT  - lipid nanoparticles
OT  - lipid-based colloidal carriers
OT  - lipophilic drugs
OT  - solubility
OT  - surfactant protein
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/30 06:00
MHDA- 2023/03/30 06:01
PMCR- 2023/02/26
CRDT- 2023/03/29 02:02
PHST- 2023/01/30 00:00 [received]
PHST- 2023/02/17 00:00 [revised]
PHST- 2023/02/21 00:00 [accepted]
PHST- 2023/03/30 06:01 [medline]
PHST- 2023/03/29 02:02 [entrez]
PHST- 2023/03/30 06:00 [pubmed]
PHST- 2023/02/26 00:00 [pmc-release]
AID - pharmaceutics15030772 [pii]
AID - pharmaceutics-15-00772 [pii]
AID - 10.3390/pharmaceutics15030772 [doi]
PST - epublish
SO  - Pharmaceutics. 2023 Feb 26;15(3):772. doi: 10.3390/pharmaceutics15030772.